Severe Acute Malnutrition in ChildhoodPhase 3BRIGHTSAMNCT06781918
Severe Acute Malnutrition and Child Development Clinical Trial in Mwanza
A Phase 3 study testing Ready to Use Therapeutic Food (RUTF) and Psychosocial stimulation in people with Severe Acute Malnutrition in Childhood, run by National Institute for Medical Research, Tanzania at 1 site in Tanzania.
Trial summary
This is a randomized clinical trial to learn whether ready-to-use therapeutic foods enriched with choline and docosahexaenoic acid (DHA) together with psychosocial stimulating activities work well to improve child development in children with severe acute malnutrition(SAM). Read more about this study
- Who is it for?
- Ages 6 to 36 months
- Conditions the study is for
- Severe Acute Malnutrition in Childhood
- What is being tested?
- Ready to Use Therapeutic Food (RUTF) and Psychosocial stimulation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 800 participants
- Where
- 1 siteTanzania
- Study dates
- 3 Feb 2025to 14 May 2026
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 36 months
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Age from 6-36 months.
- Consent given by a caregiver older than 18 years.
- Diagnosed with severe acute malnutrition (MUAC\<115 mm, or WHZ ≤-3 or bipedal pitting edema).
- Eligible for RUTF treatment (expanded below).
Who cannot join
- Conditions preventing the child from receiving interventions, e.g., peanut butter allergy or cleft palate.
- Moderate or severe disability which significantly affects normal child development (e.g., cerebral palsy or hydrocephalus), identified using a standardized screening form.
- Children of families not living in the area or planning to move from the area within the follow-up period
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Tanzania1 site
National Institute for Medical Research
Mwanza
George PrayGod, MD, PhD, +255714226305, george.praygod@nimr.or.tz
Belinda Kweka, MD, MSc, +255765025170, belinda.kweka@nimr.or.tz
About this study
Official title: BRAIN DEVELOPMENT, GROWTH AND HEALTH IN CHILDREN WITH SEVERE ACUTE MALNUTRITION
This is a randomized clinical trial to learn whether ready-to-use therapeutic foods enriched with choline and docosahexaenoic acid (DHA) together with psychosocial stimulating activities work well to improve child development in children with severe acute malnutrition(SAM). The overall question this trial aims to answer is can the health and development outcomes of children with SAM be improved through optimized nutritional treatment and integrated psychosocial support.
Researchers will compare the new ready-to-use therapeutic food and an integrated psychosocial stimulation to a standard look-alike nutritional supplement that contains no additional nutrients being investigated and the standard nutritional counseling given locally and assess its effects on child development in children with severe acute malnutrition.
Read more
Participants will:
- Be given the trial interventions which will be delivered over 12 weeks
- After the 12 weeks of intervention, participants will return for outcome evaluations (week 12 study visit), which will be repeated at follow-up visits after 24 and 48 weeks.
Read the detailed description
Background Estimated, 13.6 million children were affected by severe acute malnutrition (SAM) in 2022. Early childhood is a critical period of brain development and children exposed to malnutrition in early life have poorer school performance and lower income in adult life. Introduction of Ready to use therapeutic foods (RUTF) has greatly improved the nutritional recovery of children with SAM. However, SAM remains associated with adverse effects on child cognitive and social development. The balance in the RUTF between polyunsaturated n-6 and n-3 essential fatty acids (EFAs) in RUTF has been questioned. Essential fatty acid (EFA) status is associated with child development, and children given the standard RUTF do not improve their n-3 EFA status after recovery.
A trial in Malawi found a positive effect on cognitive scores six months after completing nutritional therapy with RUTF with added preformed docosahexaenoic acid (DHA), a long-chain polyunsaturated fatty acid (PUFA) of the n-3 series, which is essential for neural growth. There is also a potential for improving the content of other nutrients of importance for neurodevelopment in early childhood like choline, which is essential for neurotransmitter synthesis and phospholipids in the brain. Studies have indicated a synergistic relationship between n-3 EFAs and choline, suggesting that low levels of one or both may negatively impact cognition.
Deficits in child development associated with SAM are not only caused by inadequate diets. Families exposed to malnutrition are often affected by psychological distress, consequently children are likely to be offered little stimulation and responsive care. However, in practice, support for psychosocial stimulation and responsive caregiving is rarely offered during hospital-based treatment, and it is still not included in the guidelines for community-based treatment of SAM. The intensity of this intervention is difficult under the constraints of most health services in low- and middle-income countries (LMIC). More recent packages for promoting responsive care have shown some effects, but often not when implemented at scale or within systems of care.
In this study we hypothesize that optimized nutritional treatment and integrated psychosocial support can improve the health and development outcomes of children with SAM.
Specific objectives:
- to assess the effects of a modified RUTF and psychosocial stimulation, individually and combined, on attention, cognitive, motor, language and psycho-emotional development in children treated for SAM;
- to investigate the pathways of intervention effects on cognitive development by assessing the role of DHA and choline status in the child as well as caregiver factors which include caregiver-child interaction, home stimulation and maternal psychological distress;
- to assess how, why and for whom the modified RUTF and psychosocial interventions work within the trial context, perceptions of their feasibility of implementation within the routine health system, and the climate and environmental sustainability of interventions.
Methods:
This trial is designed as a 2x2 factorial randomized clinical trial to assess the effects of DHA and choline enriched vs. standard RUTF and psychosocial stimulation vs. standard counselling in management of SAM. Participants will be individually randomised to nutritional intervention arms and clusters will be randomized to psychosocial intervention arms.
The interventions will be delivered over a period of 12 weeks. After enrolment and baseline data collection, participants will receive their first RUTF sachets. They will then be requested to return to the study site for a total of seven visits during the intervention period to receive interventions. After the 12 weeks of intervention, participants will return for outcome evaluations (week 12 study visit), which will be repeated at follow-up visits after 24 and 48 weeks. The study will take place in Mwanza region, Tanzania. The trial will include children with uncomplicated SAM aged 6-36 months from eight health care facilities in Ilemela municipality, Nyamagana municipality and Magu district.
Outcomes:
The primary outcomes is the change in child development scores, which will be assessed at baseline, 12, 24 and 48 weeks and compared with intervention groups. These will assess gross, fine motor, language and psycho -emotional skills by validated tool called (MDAT) Malawi Development Assessment Tool) and neurocognitive function will be accessed by eye-tracking. Secondary outcomes will allow us to assess proximate effects of the interventions, which may mediate long-term effects on development
Analysis:
The primary analysis will be based on the intention-to-treat principle using available case data. The analysis will assess intervention effects based on the 2x2 factorial design by comparing changes in outcomes between baseline and intervention endline (i.e., 12 weeks) using a linear regression model adjusted for sex, age and month of inclusion to account for possible seasonal effects.
Secondary analysis will include assessment of intervention effects at 24- and 48-weeks follow-up using a linear mixed model to include repeated measurements. The models will include the baseline value of the outcome as fixed effect and participant as random effect to account for the correlation between measurements from the same participant. These models will also include adjustment for other variables as appropriate.
Secondary analyses will include per-protocol analyses to assess effects within groups with high compliance with the interventions
Ethics:
Ethical approval has been sought from the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research in Tanzania and the London School of Hygiene and Tropical Medicine ethics committee.
- Conditions
- Severe Acute Malnutrition in Childhood
- Being tested
- Ready to Use Therapeutic Food (RUTF), Psychosocial stimulation
- Keywords
- Severe acute malnutrition, Ready to use therapeutic food, Childhood development, Psychosocial stimulation, Choline, Docosahexaenoic acid (DHA)
- Medical subject headings
- Severe Acute Malnutrition
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ready to Use Therapeutic Food (RUTF)Dietary supplement
DHA \& Choline enriched RUTF The modified RUTF is a peanut butter paste that contains vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals the same nutrients which are the same as the standard RUTF but is fortified additionally with 250 mg of choline and 200 mg of preformed DHA per 92-gram sachet.
Standard RUTF The standard RUTF used in the BrightSAM trial is a peanut butter paste with vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals that is intended to cover the child's total daily nutritional needs. Standard RUTF will be manufactured in compliance with the specifications recommended by the Codex Alimentarius Commission17.
Psychosocial stimulationBehavioural
The psychosocial intervention has been developed and piloted for this study as a context-relevant adaptation from the WHO/UNICEF Care for Child Development package. It will be delivered in group sessions, where the primary caregiver will attend along with the child participating in the trial.
During seven sessions of approximately two hours, caregivers will be trained on a variety of subjects which include; the first four sessions will be introductory and provide the basics of nutrition, the basics of psychosocial stimulation, and play and communication practices. We will build on the increasing experience of the caregivers and provide a deeper understanding of early child development.
Standard nutritional counseling will adhere to national guidelines for pediatric management of severe acute malnutrition including nutritional counseling and psychosocial stimulation.
| Study group | Role | What they receive |
|---|---|---|
| eRUTF | Experimental | Choline and DHA enriched Ready to use therapeutic foods Receives: Dietary Supplement: Ready to Use Therapeutic Food (RUTF) |
| sRUTF | Placebo comparator | Standard ready-to-use therapeutic foods Receives: Dietary Supplement: Ready to Use Therapeutic Food (RUTF) |
| PS | Experimental | Psychosocial stimulation Receives: Behavioral: Psychosocial stimulation |
| sNC | Placebo comparator | Standard nutritional counseling and psychosocial stimualtion Receives: Behavioral: Psychosocial stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in MDAT scores
Development will be assessed by validated methods and include:
Gross motor, fine motor, language, and psycho-emotional skills assessed by the Malawi Development assessment tool (MDAT)
Measured: Assessed at baseline, 12, 24 and 48 weeks
Change in eye tracking scores
Neurocognitive function assessed by eye-tracking technique
Measured: Baseline, 12, 24 and 48 weeks
Secondary outcomes (20)
Level of caregiver stimulation and support
Caregiver stimulation and support assessed by Observations of Mother and Child Interactions (OMCI) questionnaire
Measured: Assessed at baseline, 12, 24 and 48 weeks
Fatty acid composition
- Fatty acid composition assessed by gas chromatography
Measured: at baseline and at week 12, and week 48
Mid upper arm circumference (MUAC)
- MUAC assessed using non-stretchable tape measure
Measured: Baseline, weekly, 12, 24 and 48 weeks
Mortality
Proportion of children who die during follow-up
Measured: 12, 24 and 48 weeks
Process evaluation
The process evaluation will examine the following aspects of the interventions:
- Implementation
- Mechanisms
- Context
- Acceptability
- Feasibility of implementation within the health system
- Programme theory
Measured: Interviews will be conducted after the last PS session ( Week 11) , and where possible, again with the same caregivers at long term follow-up (week 24 and 48).
Levels of choline
Levels of choline and related metabolites assessed by mass spectrometry
Measured: Baseline, 12, 24 and 48 weeks
C-reactive protein (CRP)
Serum CRP assessed as a marker of systemic inflammation
Measured: Baseline, 12, 24 and 48 weeks
Ferritin
Serum ferritin assessed as marker of iron status
Measured: Baseline, 12, 24 and 48 weeks
Level of Alanine transaminase
Serum alanine transaminase as a marker of liver function
Measured: Baseline, 12, 24 and 48 weeks
Level of Aspartate transaminase
Serum aspartate transaminase assessed as a marker of liver function
Measured: Baseline, 12, 24 and 48 weeks
Level of maternal psychological distress
Maternal psychological distress assessed by Patient Health Questionnaire 9 (PHQ-9)
Measured: Baseline, 12, 24 and 48 weeks
Status of the learning environment
The status of learning environment assessed by the Family Care Indicators (FCI) questionnaire
Measured: Baseline, 12, 24 and 48 weeks
Status of maternal social support framework
The status of maternal social support framework assessed by the Multidimensional Scale of Perceived Social Support questionnaire
Measured: Baseline, 12, 24 and 48 weeks
Morbidity
. Proportion of children with one or multiple illness episodes during follow-up
Measured: 12, 24 and 48 weeks
- Weight-for-height z-score (WHZ)
- Weight-for-height z-score (WHZ) based on length/height (m) and weight (kg) measurements'
Measured: Baseline, 12, 24 and 48 weeks
Height-for-age z-score (HAZ) , based on length/height and age)
Height-for-age z-score (HAZ) assessed based on length/height (m) and age (month)
Measured: Baseline, 12, 24 and 48 weeks
Rate of nutritional recovery at the end of intervention period
Rate of nutritional recovery at the end of intervention period, defined as WHZ > -2 and MUAC > 125 mm, and no bilateral pitting oedema for two weeks
Measured: 12
Proportion relapsing to moderate acute malnutrition (MAM) after recovery
Proportion relapsing to moderate acute malnutrition (MAM) after recovery, measured as WHZ ≤ -2 and >-3 or MUAC ≤ 125 and >115mm)
Measured: 12 weeks
Proportion relapsing to SAM after recovery
Proportion relapsing to SAM after recovery, measured as WHZ <-3, MUAC <115mm or presence of nutritional oedema, assessed at any caregiver-initiated contacts to the study site at any point during the 48 weeks of follow-up and at study visits at 24 and 48 weeks
Measured: Any time point, 24 and 48 weeks
Implementation evaluation
The implementation component will assess
- The fidelity of implementation of each component of the intervention,
- The dose (amount, frequency) of each component delivered to the children,
- Any adaptations to the intervention and why these were made,
- The reach of the interventions, provider and caregiver experience
- Perceptions, mechanisms and any unintended consequences.
Measured: Interviews will be conducted after the last PS session ( Week 11) , and where possible, again with the same caregivers at long term follow-up (week 24 and 48).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jan 2025
- Study start3 Feb 2025 (estimated)
- Primary completion14 Nov 2025 (estimated)
- Study completion14 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Severe Acute Malnutrition in ChildhoodStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- This is a 2x2 factorial randomized clinical trial which aims to study the effects of DHA and choline enriched ready to use therapeutic foods and psychosocial stimulation in the management of children with severe acute malnutrition.
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 800 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Institute for Medical Research, Tanzania
- Sponsor type
- Other government
- Collaborators
- University of Liverpool, Bugando Medical Centre, University of Turku, Copenhagen University Hospital, Rigshospitalet, University of Copenhagen, Sokoine University of Agriculture, London School of Hygiene and Tropical Medicine
- Responsible party
- Principal investigator, Dr George PrayGod, National Institute for Medical Research, Tanzania
- Investigators
- Mette Olsen, MSc, PhD, Principal investigator, Copenhagen University Hospital, RigshospitaletGeorge PrayGod, MD, PhD, Principal investigator, National Institute for Medical Research
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06781918
- Sponsor's protocol ID
- DFC file no. 23-13-RH
- Other IDs
- DFC file no. 23-13-RH
- Acronym
- BRIGHTSAM
- Status last verified
- Jan 2025
- First submitted
- 3 Dec 2024
- Last updated
- 17 Jan 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Grantham-McGregor S, Stewart ME, Schofield WN. Effect of long-term psychosocial stimulation on mental development of severely malnourished children. Lancet. 1980 Oct 11;2(8198):785-9. doi: 10.1016/s0140-6736(80)90395-5.
PubMed 6107460Olsen MF, Iuel-Brockdorff AS, Yameogo CW, Cichon B, Fabiansen C, Filteau S, Phelan K, Ouedraogo A, Wells JC, Briend A, Michaelsen KF, Lauritzen L, Ritz C, Ashorn P, Christensen VB, Gladstone M, Friis H. Early development in children with moderate acute malnutrition: A cross-sectional study in Burkina Faso. Matern Child Nutr. 2020 Apr;16(2):e12928. doi: 10.1111/mcn.12928. Epub 2019 Dec 11.
PubMed 31823490Stephenson K, Callaghan-Gillespie M, Maleta K, Nkhoma M, George M, Park HG, Lee R, Humphries-Cuff I, Lacombe RJS, Wegner DR, Canfield RL, Brenna JT, Manary MJ. Low linoleic acid foods with added DHA given to Malawian children with severe acute malnutrition improve cognition: a randomized, triple-blinded, controlled clinical trial. Am J Clin Nutr. 2022 May 1;115(5):1322-1333. doi: 10.1093/ajcn/nqab363.
PubMed 34726694Gera T, Pena-Rosas JP, Boy-Mena E, Sachdev HS. Lipid based nutrient supplements (LNS) for treatment of children (6 months to 59 months) with moderate acute malnutrition (MAM): A systematic review. PLoS One. 2017 Sep 21;12(9):e0182096. doi: 10.1371/journal.pone.0182096. eCollection 2017.
PubMed 28934235Lelijveld N, Jalloh AA, Kampondeni SD, Seal A, Wells JC, Goyheneix M, Chimwezi E, Mallewa M, Nyirenda MJ, Heyderman RS, Kerac M. Brain MRI and cognitive function seven years after surviving an episode of severe acute malnutrition in a cohort of Malawian children. Public Health Nutr. 2019 Jun;22(8):1406-1414. doi: 10.1017/S1368980018003282. Epub 2018 Dec 3.
PubMed 30501662Hoddinott J, Behrman JR, Maluccio JA, Melgar P, Quisumbing AR, Ramirez-Zea M, Stein AD, Yount KM, Martorell R. Adult consequences of growth failure in early childhood. Am J Clin Nutr. 2013 Nov;98(5):1170-8. doi: 10.3945/ajcn.113.064584. Epub 2013 Sep 4.
PubMed 24004889
Study at a glance
From the registry record, last updated by the sponsor on 17 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- BRAIN DEVELOPMENT, GROWTH AND HEALTH IN CHILDREN WITH SEVERE ACUTE MALNUTRITION
- ClinicalTrials.gov ID
- NCT06781918
- Acronym / sponsor ID
- BRIGHTSAM / DFC file no. 23-13-RH
- Conditions
- Severe Acute Malnutrition in Childhood
- Keywords
- Severe acute malnutrition, Ready to use therapeutic food, Childhood development, Psychosocial stimulation, Choline, Docosahexaenoic acid (DHA)
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 800 participants (estimated)
- Lead sponsor
- National Institute for Medical Research, TanzaniaOther government
- Collaborators
- University of Liverpool, Bugando Medical Centre, University of Turku, Copenhagen University Hospital, Rigshospitalet, University of Copenhagen, Sokoine University of Agriculture, London School of Hygiene and Tropical Medicine
- Study start
- 3 Feb 2025 (estimated)
- Primary completion
- 14 Nov 2025 (estimated)
- Study completion
- 14 May 2026 (estimated)
- First posted
- 17 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized clinical trial to learn whether ready-to-use therapeutic foods enriched with choline and docosahexaenoic acid (DHA) together with psychosocial stimulating activities work well to improve child development in children with severe acute malnutrition(SAM). The overall question this trial aims to answer is can the health and development outcomes of children with SAM be improved through optimized nutritional treatment and integrated psychosocial support.
Researchers will compare the new ready-to-use therapeutic food and an integrated psychosocial stimulation to a standard look-alike nutritional supplement that contains no additional nutrients being investigated and the standard nutritional counseling given locally and assess its effects on child development in children with severe acute malnutrition.
Participants will:
- Be given the trial interventions which will be delivered over 12 weeks
- After the 12 weeks of intervention, participants will return for outcome evaluations (week 12 study visit), which will be repeated at follow-up visits after 24 and 48 weeks.
Detailed description
Background Estimated, 13.6 million children were affected by severe acute malnutrition (SAM) in 2022. Early childhood is a critical period of brain development and children exposed to malnutrition in early life have poorer school performance and lower income in adult life. Introduction of Ready to use therapeutic foods (RUTF) has greatly improved the nutritional recovery of children with SAM. However, SAM remains associated with adverse effects on child cognitive and social development. The balance in the RUTF between polyunsaturated n-6 and n-3 essential fatty acids (EFAs) in RUTF has been questioned. Essential fatty acid (EFA) status is associated with child development, and children given the standard RUTF do not improve their n-3 EFA status after recovery.
A trial in Malawi found a positive effect on cognitive scores six months after completing nutritional therapy with RUTF with added preformed docosahexaenoic acid (DHA), a long-chain polyunsaturated fatty acid (PUFA) of the n-3 series, which is essential for neural growth. There is also a potential for improving the content of other nutrients of importance for neurodevelopment in early childhood like choline, which is essential for neurotransmitter synthesis and phospholipids in the brain. Studies have indicated a synergistic relationship between n-3 EFAs and choline, suggesting that low levels of one or both may negatively impact cognition.
Deficits in child development associated with SAM are not only caused by inadequate diets. Families exposed to malnutrition are often affected by psychological distress, consequently children are likely to be offered little stimulation and responsive care. However, in practice, support for psychosocial stimulation and responsive caregiving is rarely offered during hospital-based treatment, and it is still not included in the guidelines for community-based treatment of SAM. The intensity of this intervention is difficult under the constraints of most health services in low- and middle-income countries (LMIC). More recent packages for promoting responsive care have shown some effects, but often not when implemented at scale or within systems of care.
In this study we hypothesize that optimized nutritional treatment and integrated psychosocial support can improve the health and development outcomes of children with SAM.
Specific objectives:
- to assess the effects of a modified RUTF and psychosocial stimulation, individually and combined, on attention, cognitive, motor, language and psycho-emotional development in children treated for SAM;
- to investigate the pathways of intervention effects on cognitive development by assessing the role of DHA and choline status in the child as well as caregiver factors which include caregiver-child interaction, home stimulation and maternal psychological distress;
- to assess how, why and for whom the modified RUTF and psychosocial interventions work within the trial context, perceptions of their feasibility of implementation within the routine health system, and the climate and environmental sustainability of interventions.
Methods:
This trial is designed as a 2x2 factorial randomized clinical trial to assess the effects of DHA and choline enriched vs. standard RUTF and psychosocial stimulation vs. standard counselling in management of SAM. Participants will be individually randomised to nutritional intervention arms and clusters will be randomized to psychosocial intervention arms.
The interventions will be delivered over a period of 12 weeks. After enrolment and baseline data collection, participants will receive their first RUTF sachets. They will then be requested to return to the study site for a total of seven visits during the intervention period to receive interventions. After the 12 weeks of intervention, participants will return for outcome evaluations (week 12 study visit), which will be repeated at follow-up visits after 24 and 48 weeks. The study will take place in Mwanza region, Tanzania. The trial will include children with uncomplicated SAM aged 6-36 months from eight health care facilities in Ilemela municipality, Nyamagana municipality and Magu district.
Outcomes:
The primary outcomes is the change in child development scores, which will be assessed at baseline, 12, 24 and 48 weeks and compared with intervention groups. These will assess gross, fine motor, language and psycho -emotional skills by validated tool called (MDAT) Malawi Development Assessment Tool) and neurocognitive function will be accessed by eye-tracking. Secondary outcomes will allow us to assess proximate effects of the interventions, which may mediate long-term effects on development
Analysis:
The primary analysis will be based on the intention-to-treat principle using available case data. The analysis will assess intervention effects based on the 2x2 factorial design by comparing changes in outcomes between baseline and intervention endline (i.e., 12 weeks) using a linear regression model adjusted for sex, age and month of inclusion to account for possible seasonal effects.
Secondary analysis will include assessment of intervention effects at 24- and 48-weeks follow-up using a linear mixed model to include repeated measurements. The models will include the baseline value of the outcome as fixed effect and participant as random effect to account for the correlation between measurements from the same participant. These models will also include adjustment for other variables as appropriate.
Secondary analyses will include per-protocol analyses to assess effects within groups with high compliance with the interventions
Ethics:
Ethical approval has been sought from the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research in Tanzania and the London School of Hygiene and Tropical Medicine ethics committee.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Double blind (participant, care provider)
- Number of arms
- 4
- Model description
- This is a 2x2 factorial randomized clinical trial which aims to study the effects of DHA and choline enriched ready to use therapeutic foods and psychosocial stimulation in the management of children with severe acute malnutrition.
| Arm | Type | Receives |
|---|---|---|
| eRUTF | Experimental | Dietary Supplement: Ready to Use Therapeutic Food (RUTF)Choline and DHA enriched Ready to use therapeutic foods |
| sRUTF | Placebo comparator | Dietary Supplement: Ready to Use Therapeutic Food (RUTF)Standard ready-to-use therapeutic foods |
| PS | Experimental | Behavioral: Psychosocial stimulationPsychosocial stimulation |
| sNC | Placebo comparator | Behavioral: Psychosocial stimulationStandard nutritional counseling and psychosocial stimualtion |
Who may qualify
- Ages
- 6 to 36 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Age from 6-36 months.
- Consent given by a caregiver older than 18 years.
- Diagnosed with severe acute malnutrition (MUAC\<115 mm, or WHZ ≤-3 or bipedal pitting edema).
- Eligible for RUTF treatment (expanded below).
Key exclusion criteria (3 listed)
- Conditions preventing the child from receiving interventions, e.g., peanut butter allergy or cleft palate.
- Moderate or severe disability which significantly affects normal child development (e.g., cerebral palsy or hydrocephalus), identified using a standardized screening form.
- Children of families not living in the area or planning to move from the area within the follow-up period
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ready to Use Therapeutic Food (RUTF)DHA \& Choline enriched RUTF The modified RUTF is a peanut butter paste that contains vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals the same nutrients which are the same as the standard RUTF but is fortified additionally with 250 mg of choline and 200 mg of preformed DHA per 92-gram sachet. Standard RUTF The standard RUTF used in the BrightSAM trial is a peanut butter paste with vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals that is intended to cover the child's total daily nutritional needs. Standard RUTF will be manufactured in compliance with the specifications recommended by the Codex Alimentarius Commission17. | Dietary supplement | eRUTF, sRUTF |
| Psychosocial stimulationThe psychosocial intervention has been developed and piloted for this study as a context-relevant adaptation from the WHO/UNICEF Care for Child Development package. It will be delivered in group sessions, where the primary caregiver will attend along with the child participating in the trial. During seven sessions of approximately two hours, caregivers will be trained on a variety of subjects which include; the first four sessions will be introductory and provide the basics of nutrition, the basics of psychosocial stimulation, and play and communication practices. We will build on the increasing experience of the caregivers and provide a deeper understanding of early child development. Standard nutritional counseling will adhere to national guidelines for pediatric management of severe acute malnutrition including nutritional counseling and psychosocial stimulation. | Behavioural | PS, sNC |
Primary outcome
Change in MDAT scores
Time frame: Assessed at baseline, 12, 24 and 48 weeks
Development will be assessed by validated methods and include: Gross motor, fine motor, language, and psycho-emotional skills assessed by the Malawi Development assessment tool (MDAT)
Change in eye tracking scores
Time frame: Baseline, 12, 24 and 48 weeks
Neurocognitive function assessed by eye-tracking technique
20 secondary outcomes
Level of caregiver stimulation and support
Time frame: Assessed at baseline, 12, 24 and 48 weeks
Fatty acid composition
Time frame: at baseline and at week 12, and week 48
Mid upper arm circumference (MUAC)
Time frame: Baseline, weekly, 12, 24 and 48 weeks
Mortality
Time frame: 12, 24 and 48 weeks
Process evaluation
Time frame: Interviews will be conducted after the last PS session ( Week 11) , and where possible, again with the same caregivers at long term follow-up (week 24 and 48).
Levels of choline
Time frame: Baseline, 12, 24 and 48 weeks
C-reactive protein (CRP)
Time frame: Baseline, 12, 24 and 48 weeks
Ferritin
Time frame: Baseline, 12, 24 and 48 weeks
Level of Alanine transaminase
Time frame: Baseline, 12, 24 and 48 weeks
Level of Aspartate transaminase
Time frame: Baseline, 12, 24 and 48 weeks
Level of maternal psychological distress
Time frame: Baseline, 12, 24 and 48 weeks
Status of the learning environment
Time frame: Baseline, 12, 24 and 48 weeks
Status of maternal social support framework
Time frame: Baseline, 12, 24 and 48 weeks
Morbidity
Time frame: 12, 24 and 48 weeks
- Weight-for-height z-score (WHZ)
Time frame: Baseline, 12, 24 and 48 weeks
Height-for-age z-score (HAZ) , based on length/height and age)
Time frame: Baseline, 12, 24 and 48 weeks
Rate of nutritional recovery at the end of intervention period
Time frame: 12
Proportion relapsing to moderate acute malnutrition (MAM) after recovery
Time frame: 12 weeks
Proportion relapsing to SAM after recovery
Time frame: Any time point, 24 and 48 weeks
Implementation evaluation
Time frame: Interviews will be conducted after the last PS session ( Week 11) , and where possible, again with the same caregivers at long term follow-up (week 24 and 48).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jan 2025.
- Results publication: PubMed 6107460Grantham-McGregor S, Stewart ME, Schofield WN. Effect of long-term psychosocial stimulation on mental development of severely malnourished children. Lancet. 1980 Oct 11;2(8198):785-9. doi: 10.1016/s0140-6736(80)90395-5.
- Results publication: PubMed 31823490Olsen MF, Iuel-Brockdorff AS, Yameogo CW, Cichon B, Fabiansen C, Filteau S, Phelan K, Ouedraogo A, Wells JC, Briend A, Michaelsen KF, Lauritzen L, Ritz C, Ashorn P, Christensen VB, Gladstone M, Friis H. Early development in children with moderate acute malnutrition: A cross-sectional study in Burkina Faso. Matern Child Nutr. 2020 Apr;16(2):e12928. doi: 10.1111/mcn.12928. Epub 2019 Dec 11.
- Results publication: PubMed 34726694Stephenson K, Callaghan-Gillespie M, Maleta K, Nkhoma M, George M, Park HG, Lee R, Humphries-Cuff I, Lacombe RJS, Wegner DR, Canfield RL, Brenna JT, Manary MJ. Low linoleic acid foods with added DHA given to Malawian children with severe acute malnutrition improve cognition: a randomized, triple-blinded, controlled clinical trial. Am J Clin Nutr. 2022 May 1;115(5):1322-1333. doi: 10.1093/ajcn/nqab363.
- Results publication: PubMed 28934235Gera T, Pena-Rosas JP, Boy-Mena E, Sachdev HS. Lipid based nutrient supplements (LNS) for treatment of children (6 months to 59 months) with moderate acute malnutrition (MAM): A systematic review. PLoS One. 2017 Sep 21;12(9):e0182096. doi: 10.1371/journal.pone.0182096. eCollection 2017.
- Results publication: PubMed 30501662Lelijveld N, Jalloh AA, Kampondeni SD, Seal A, Wells JC, Goyheneix M, Chimwezi E, Mallewa M, Nyirenda MJ, Heyderman RS, Kerac M. Brain MRI and cognitive function seven years after surviving an episode of severe acute malnutrition in a cohort of Malawian children. Public Health Nutr. 2019 Jun;22(8):1406-1414. doi: 10.1017/S1368980018003282. Epub 2018 Dec 3.
- Results publication: PubMed 24004889Hoddinott J, Behrman JR, Maluccio JA, Melgar P, Quisumbing AR, Ramirez-Zea M, Stein AD, Yount KM, Martorell R. Adult consequences of growth failure in early childhood. Am J Clin Nutr. 2013 Nov;98(5):1170-8. doi: 10.3945/ajcn.113.064584. Epub 2013 Sep 4.
- Levels and trends in child malnutrition: UNICEF/WHO/World Bank Group joint child malnutrition estimates: key findings of the 2023 editionLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Severe Acute Malnutrition in Childhood
Not yet recruiting
The Relapse to Acute Malnutrition Prevention (RAMP) Trial
Acute Malnutrition in Childhood, Acute Malnutrition, Severe
RecruitingPhase 4
Opportunistic Pneumococcal Immunisation Trial in MALnutrition
Severe Acute Malnutrition in Childhood, Pneumococcal Disease
Active, not recruiting
Regular Growth Monitoring (RGM) of Young Children in Guinea-Bissau
Severe Acute Malnutrition, Moderate Acute Malnutrition (MAM)
Not yet recruiting
Treatment of Severe Acute Malnutrition in Children 6 to 59 Months Old With Standard Ready To Use Therapeutic Food Compared to a Newly Formulated Lipid Optimized Ready To Use Therapeutic Food
Severe Acute Malnutrition in Childhood, Malnutrition, Child
Recruiting
The DECIDE-TB Trial; Validation of Treatment Decision Algorithms for Childhood Tuberculosis
Tuberculosis, Child Health
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mette Olsen, MSc, PhD principal investigator
Copenhagen University Hospital, Rigshospitalet
George PrayGod, MD, PhD principal investigator
National Institute for Medical Research
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Ready to Use Therapeutic Food (RUTF) and Psychosocial stimulation in people with Severe Acute Malnutrition in Childhood, run by National Institute for Medical Research, Tanzania at 1 site in Tanzania.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Tanzania. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact George PrayGod, MD, PhD (+255714226305, george.praygod@nimr.or.tz), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in MDAT scores (time frame: Assessed at baseline, 12, 24 and 48 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06781918, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2025.